Ernexa Therapeutics (ERNAW) Long-Term Debt Issuances (2012 - 2025)

Ernexa Therapeutics (ERNAW) has 11 years of Long-Term Debt Issuances data on file, last reported at $2.2 million in Q1 2025.

• Quarterly Long-Term Debt Issuances rose 60.14% year-over-year to $2.2 million in Q1 2025, while the trailing twelve-month figure through Dec 2025 was $2.2 million (down 42.11% YoY) and the FY2025 annual result came in at $2.2 million, down 42.11% from the prior year.
• Long-Term Debt Issuances slipped to $2.2 million in Q1 2025, from $2.5 million in the prior quarter.
• In the past five years, Long-Term Debt Issuances ranged from a high of $16.5 million in Q4 2023 to a low of $410000.0 in Q4 2021.
• A 4-year average of $4.6 million and a median of $2.2 million in 2025 frame the typical range for Long-Term Debt Issuances.
• Annual changes were most pronounced in 2021 — Long-Term Debt Issuances surged 232.3% — and 2025, when it surged 60.14%.
• Tracing ERNAW's Long-Term Debt Issuances over 4 years: stood at $410000.0 in 2021, then jumped by 3924.39% to $16.5 million in 2023, then sank by 84.96% to $2.5 million in 2024, then fell by 9.35% to $2.2 million in 2025.
• The last three Long-Term Debt Issuances figures came in at $2.2 million (Q1 2025), $2.5 million (Q3 2024), and $1.4 million (Q1 2024), per Business Quant data.